TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Last trade$1.40
Day change+$0.05 (+3.70%)
Day range$1.30 – $1.46
Volume25,109
Market cap$23M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$22.86M
Price / earnings
—
Price / book
-0.83×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.42×
Profitability
Earnings per share
-$2.73
Return on assets
-30.65%
Return on equity
167.12%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.02×
Current ratio
1.97×
Quick ratio
1.97×
Cash ratio
1.55×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$22.61M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RNAZ, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.54M
$2.22M
$1.76M
$1.4M
$1.66M
$951.65K
$1.45M
$938.03K
Research and development
$3.69M
$15.53M
$5.48M
$3.16M
$2.57M
$2.22M
$3.64M
$1.23M
Total operating expenses
$6.79M
$17.76M
$16.03M
$4.56M
$4.22M
$3.17M
$5.09M
$2.17M
Operating income
-$6.79M
-$17.76M
-$16.03M
-$4.56M
-$4.22M
-$3.17M
-$5.09M
-$2.17M
Interest expense
$0
$0
-$542
-$5.96K
$0
-$114
-$1.83K
-$10.79K
Income before taxes
-$6.75M
-$17.55M
-$13.22M
-$4.86M
-$4.28M
-$12.09M
-$5.92M
-$2.32M
Income taxes
$300
$231.31K
$226.07K
$0
$0
$0
$0
$0
Net income
-$6.75M
-$17.79M
-$13.44M
-$4.86M
-$4.28M
-$12.09M
-$5.92M
-$2.32M
Net income attributable to common shareholders
-$6.87M
-$19.51M
-$15.05M
-$4.86M
-$4.28M
-$12.09M
-$5.95M
-$2.32M
EBITDA
-$6.77M
-$17.73M
-$7.19M
-$4.56M
-$4.21M
-$3.16M
-$5.08M
-$2.15M
Basic earnings per share
-$7.17
-$21.28
-$16.38
-$5.82
-$5.13
-$70.16
-$281.26
-$146.06
Diluted earnings per share
-$7.17
-$21.28
-$16.38
-$5.82
-$5.13
-$70.16
-$281.26
-$146.06
Recent news
Company coverage with links to the original publishers.
Natera announced a strategic collaboration with TransCode Therapeutics to use its Signatera MRD test for identifying eligible patients in a Phase 2a trial evaluating TTX-MC138, an investigational therapy targeting miR-10b in colorectal cancer patients. The partnership aims to accelerate patient enrollment by detecting residual cancer in patients with no detectable disease on imaging, addressing an unmet medical need in early cancer recurrence intervention.
A comprehensive market report on checkpoint inhibitors covering 50+ companies and 60+ drugs in oncology. The report highlights key players like Bristol Myers Squibb, Genentech, and emerging companies such as OncoC4 and Transcode Therapeutics, with analysis of marketed therapies, pipeline products, and recent industry collaborations and acquisitions in the immuno-oncology space.
TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors. Stover brings over 30 years of executive leadership experience in life sciences, drug development, and capital formation. He will join the Audit and Nominating Committees as the company advances its RNA and immuno-oncology pipeline for cancer treatment.
TransCode Therapeutics announced the acquisition of Polynoma LLC, a biotechnology firm focused on immuno-oncology, and received a $25 million strategic investment from CK Life Sciences. The deal includes stock issuance and will support the advancement of TransCode's microRNA-based therapeutic into Phase 2 clinical trials.
U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.